Preclinical and clinical development of palbociclib and future perspectives-Reference-Cited by-同舟云学术

Preclinical and clinical development of palbociclib and future perspectives

Published:2018-03-21 Issue:9 Volume:20 Page:1136-1144
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

de Dueñas E. Martínez^ORCID,Gavila-Gregori J.,Olmos-Antón S.,Santaballa-Bertrán A.,Lluch-Hernández A.,Espinal-Domínguez E. J.,Rivero-Silva M.,Llombart-Cussac A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s12094-018-1850-3/fulltext.html

Reference31 articles.

1. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.

2. (FDA) USFDAUS. Palbociclib (IBRANCE). 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549978.htm . Accessed 30 June 2017.

3. (EMA) EMA. Ibrance (palbociclib). 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003853/human_med_002034.jsp&mid=WC0b01ac058001d124 . Accessed 30 June 2017.

4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

5. Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 2014;16:207.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors;European Journal of Pharmacology;2024-05

2. Differential effects of dietary polyphenols on oral pharmacokinetics of cyclin-dependent kinase inhibitors in rats: a mechanistic framework for in vitro–in vivo extrapolation;Journal of Pharmacy and Pharmacology;2023-12-12

3. The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models;Breast Cancer: Targets and Therapy;2023-12

4. Azaindole derivatives as potential kinase inhibitors and their SARs elucidation;European Journal of Medicinal Chemistry;2023-10

5. Quinazolinone derivatives as new potential CDK4/6 inhibitors, apoptosis inducers and radiosensitizers for breast cancer;Future Medicinal Chemistry;2023-07